Stock Analysis
- Switzerland
- /
- Life Sciences
- /
- SWX:SKAN
A Look At The Intrinsic Value Of SKAN Group AG (VTX:SKAN)
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, SKAN Group fair value estimate is CHF83.59
- With CHF77.90 share price, SKAN Group appears to be trading close to its estimated fair value
- Peers of SKAN Group are currently trading on average at a 42% premium
In this article we are going to estimate the intrinsic value of SKAN Group AG (VTX:SKAN) by taking the expected future cash flows and discounting them to their present value. This will be done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
See our latest analysis for SKAN Group
What's The Estimated Valuation?
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CHF, Millions) | CHF16.4m | CHF36.8m | CHF46.3m | CHF58.4m | CHF67.1m | CHF74.2m | CHF79.6m | CHF83.8m | CHF86.9m | CHF89.3m |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Analyst x1 | Analyst x1 | Est @ 14.91% | Est @ 10.49% | Est @ 7.40% | Est @ 5.24% | Est @ 3.72% | Est @ 2.66% |
Present Value (CHF, Millions) Discounted @ 4.4% | CHF15.7 | CHF33.8 | CHF40.7 | CHF49.2 | CHF54.2 | CHF57.4 | CHF59.0 | CHF59.5 | CHF59.1 | CHF58.2 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CHF487m
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.2%. We discount the terminal cash flows to today's value at a cost of equity of 4.4%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CHF89m× (1 + 0.2%) ÷ (4.4%– 0.2%) = CHF2.1b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CHF2.1b÷ ( 1 + 4.4%)10= CHF1.4b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CHF1.9b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of CHF77.9, the company appears about fair value at a 6.8% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at SKAN Group as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.4%, which is based on a levered beta of 0.910. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for SKAN Group
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Dividend is low compared to the top 25% of dividend payers in the Life Sciences market.
- Annual earnings are forecast to grow faster than the Swiss market.
- Current share price is below our estimate of fair value.
- No apparent threats visible for SKAN.
Next Steps:
Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For SKAN Group, there are three essential aspects you should explore:
- Risks: For example, we've discovered 1 warning sign for SKAN Group that you should be aware of before investing here.
- Future Earnings: How does SKAN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Swiss stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SWX:SKAN
SKAN Group
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally.